INFECTIOUS DISEASE AND VACCINE CRO
Where disease spreads, we’re already there
Outbreak timing. Hard-to-reach populations. Safety at scale. AKEURA plans for them before the first participant enrolls, from Phase I vaccine trials through post-licensure effectiveness and safety studies.
Meet our experts
Vaccine development is in our blood
-
400+
infectious disease and vaccine studies
-
40+
vaccine targets across our portfolio
-
500k+
participants across 60+ countries
-
100+
studies in 10+ African countries
Deep infectious disease expertise,
pathogen by pathogen
Seasonality, transmission, and the settings where a disease circulates all change how a study should run. AKEURA’s infectious disease CRO services are planned around them, from vaccine development through real-world evidence.
Vaccines
From first dose to real-world effectiveness
Maternal, pediatric, adult, and older-adult vaccine studies, from Phase I through post-licensure
Our vaccine specialists cover dose and schedule selection, immunogenicity, efficacy, and safety, then follow through with effectiveness and burden-of-disease studies once your vaccine is licensed.
Respiratory infections
Seasons open fast and close faster
RSV, COVID-19, influenza, pneumococcal disease, pertussis, and human metapneumovirus
Our epidemiologists track disease burden and seasonality to put the right population in the right geography at the right time, so enrollment opens when the season does.
Tropical and vector-borne diseases
Endemic regions need local know-how
Malaria, dengue, chikungunya, Lyme disease, Japanese encephalitis, and yellow fever
Our own teams work where these diseases circulate, with site networks across Africa that know the local regulations, communities, and seasons before your study arrives.
Bacterial infections and resistance
Where antimicrobial resistance raises the stakes
Tuberculosis, meningococcal disease, E. coli, Group B strep, and cholera
From vaccine trials to studies of disease burden, we generate evidence on bacterial pathogens and drug-resistant strains across clinical and real-world settings.
Chronic viral infections
Evidence that keeps pace with chronic infection
HIV, viral hepatitis, HPV, herpes zoster, and other chronic and sexually transmitted infections
These studies often run for years. We plan follow-up and participant retention from the start, across clinical trials and real-world studies, so your data holds to the final visit.
Emerging and epidemic-prone diseases
Outbreaks don't wait for a perfect protocol
Lassa fever, Ebola, Zika, mpox, and other emerging and epidemic-prone threats
When an outbreak hits, timing is everything. Our epidemiologists and local teams build the incidence evidence that future vaccine studies depend on, before the next wave arrives.
Led by people who built their careers in vaccines
Meet the infectious disease and vaccine specialists behind your study.
Direct access to deep expertise
Laurence De Moerlooze
Global Head of Infectious Diseases and Vaccines
[Short bio to come.]
Edward Sobe Yarig
Adriana Bastidas
Kaatje Bollaerts
Bradford Gessner
[Short bio to come.]
Ola Polkowska-Kramek
[Short bio to come.]
In-house scientific experts
Our medical monitors, epidemiologists, and therapeutic-area specialists are in protocol design meetings, on safety calls, and on the paper when the results publish.
Outbreaks move fast. So do we.
Incidence shifts. Seasons close. Infrastructure varies.
Our studies are led by senior experts who built their careers inside vaccine development.
Evidence from the field
White papers, fact sheets, and case studies from our infectious disease and vaccine teams.
White paper
Research at the speed of outbreak
With more than 1,000 confirmed cases and no licensed Bundibugyo-specific vaccine, the race to generate evidence is already on. Our experts share what past Ebola trials got right and how sponsors, regulators, and communities can move faster without compromising safety, ethics, or trust. Download the white paper for practical recommendations to start studies faster in outbreak settings.
Fact sheet
Vaccine development is in our blood
Our teams bring 25+ years of vaccine research across 40+ targets, from respiratory viruses and tuberculosis to tropical and emerging diseases. With 400+ studies, 500,000+ participants, and our own teams on the ground across Africa, we know the pathogen, the populations, and the places where disease circulates. Download the fact sheet to see how we support programs from Phase I through post-licensure.
Case study
Some partnerships last a study. Ours lasted a vaccine program.
Over 15 years, we grew from a functional service provider to a full-service partner, managing 10+ active studies at once without losing speed. When a new regulatory requirement came up mid-trial, our senior experts modified the protocol within days. Download the case study to see how we helped a mid-size biotech reach licensure.
Support at every stage of development
Early phase clinical development
Confident first steps from first dose to proof of concept, with answers your next study can trust
Late phase clinical development
Phase IIb to Phase IV trials at scale, built to carry your program through approval and beyond
Real-world evidence studies
Regulatory-grade post-approval safety and effectiveness studies, led by RWE specialists who stay within reach
Frequently asked questions
Answers to your questions about our infectious disease and vaccine expertise
AKEURA runs vaccine effectiveness, safety, burden-of-disease, utilization, and treatment-pattern studies. Designs include registries, database and electronic health record analyses, prospective observational studies, and collaborative evidence networks.
Connect with an expert
Tell us what you need.
Your message goes to the team that handles your study.